Revolution Medicines, Inc.
RVMD
Rank in Stocks
#644
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Share Price
$176.71
Last synced: 2026-10-16
Market Cap
$37.88B
Change (1 day)
-6.63%
Change (1 year)
226.64%
Country
US
Trade Revolution Medicines, Inc. (RVMD)
Category
Healthcare
EPS for Revolution Medicines, Inc. (RVMD)
EPS as of June 2026 TTM: $-8.86
According to Revolution Medicines, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-8.86. At the end of 2023 the company had a EPS of $-3.86 an increase over its 2022 EPS that were of $-3.08.
EPS history for Revolution Medicines, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-8.86 | 147.49% |
| 2024 | $-3.58 | -7.25% |
| 2023 | $-3.86 | 25.32% |
| 2022 | $-3.08 | 24.70% |
| 2021 | $-2.47 | 52.47% |
| 2020 | $-1.62 | 23.66% |
| 2019 | $-1.31 | 13.91% |
| 2018 | $-1.15 | 35.29% |
| 2017 | $-0.85 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -295.49% |
US
|
|
| $-7.98 | -9.93% |
US
|
|
| $-5.29 | -40.29% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -413.09% |
NL
|
